PRMT6 and hepatocellular carcinoma: A study showed that PRMT6 promotes PKM2 nuclear translocation, leading to increased aerobic glycolysis in HCC, while the addition of 2-DG (a well-known inhibitor of glycolysis) sufficiently reverses PRMT6 deficiency-mediated tumor progression and sorafenib resistance [61].